116041-83-9

Upstream product

• 136007-71-1 1-<(4-fluorobenzoyl)oxy>-2,4-dichlorobenzene 
• 114865-95-1 (3,5-dichloro-2-hydroxyphenyl)-(4-fluorophenyl)methanone 
• 403-43-0 4-fluorobenzoyl chloride 
• 120-83-2 2,4-dichlorophenol 
• 136007-72-2 2,4-dichloro-6-phenol 
• 116041-82-8 2,4-dichloro-6-phenol 
• 116041-81-7 O-<4,6-dichloro-2-phenyl>N,N-dimethylthiocarbamate 

Downstream Products

• 116041-84-0 4,6-dichloro-2-thiphenol 
• 116041-87-3 ((2S,4R)-2-{2-[Bis-(4-fluoro-phenyl)-methyl]-4,6-dichloro-phenylsulfanylmethyl}-6-methoxy-tetrahydro-pyran-4-yloxy)-tert-butyl-diphenyl-silane 

Relevant academic research and scientific papers

Synthesis and Biological activity of new HMG-CoA reductase inhibitors. 3.1,2 lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids

A group of 43 optically active sodium carboxylates (11a-qq and the corresponding lactones 4 were prepared from respective phenols 8 according to Schemes I-III. Phenols 8 were synthesized from commercially available compounds according to Schemes IV-IX. A

3-demethyl-4-fluoromevalonic acid derivatives, a process for the preparation thereof, pharmaceutical products based on these compounds, the use thereof, and intermediates

3-Demethyl-4-fluoromevalonic acid derivatives, a process for the preparation thereof, pharmaceutical products based on these compounds, the use thereof, and intermediates 3-Demethyl-4-fluoromevalonic acid derivatives of the formula I, and the corresponding dihydroxy carboxylic acid derivatives of the formula II STR1 in which R, X and Y have the stated meanings, processes for the preparation of these compounds, the use thereof as medicaments, and pharmaceutical products are described. In addition, new intermediates for the preparation of the compounds of the formula I and formula II are described.